Sonoma Pharmaceuticals announces Q2 earnings per share of 32 cents, compared to a loss of 59 cents in the same period last year.

Written by Emily J. Thompson, Senior Investment Analyst

SNOA-1.8%

Updated: Nov 04 2025

0mins

Q2 Revenue Growth: Sonoma Pharmaceuticals reported a record Q2 revenue of $5.6 million, up from $3.6 million the previous year.
CEO's Statement: CEO Amy Trombly highlighted the achievement as a result of the team's efforts in expanding distribution, launching new products, and securing regulatory approvals.
Future Expectations: The company anticipates quarterly fluctuations but expects a positive growth trajectory with increasing adoption of its products.
Industry Position: Sonoma aims to solidify its status as the global leader in the HOCl industry.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SNOA?" and start using high-conviction signals backed by rigorous historical data.

SNOA

$3.28+Infinity%1D

Analyst Views on SNOA

About SNOA

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for SNOA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy SNOA?

Get Started Free